Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study was carried out to evaluate the effect of telemonitoring service to be given to patients kept under quarantine during the COVID 19 pandemic on anxiety and quality of life.
The COVID 19 pandemic, which continues today, has caused radical changes in social, cultural, education, and health systems around the world(Zhang and Liu 2020; Wang et all 2020; Alipour &Abdolahzadeh 2020). In this period, health care providers tried to use telehealth services as a good alternative to solve the problems caused by quarantine, social isolation practices to reduce the rate of transmission of the disease, and the limitation of physical access to health services due to the risk of transmission.
Thus, the use of telehealth applications, which first started in the 1950s, gained momentum especially during the pandemic period (Byrne 2020; Lurie & Carr 2018; Clipper 2020; Fagherazzi 2020). Telehealth applications, which have the opportunity to be widely used during the COVID 19 pandemic period, are generally a system that provides two-way communication between healthcare professionals and patients and includes image, speech, and digital communication technologies (Hazin & Qaddoumi, 2010; Merz et all 2021; Bryne 2020). Tele-monitoring is a good option to support patients in the management of existing physical symptoms of quarantined patients who are isolated at home, except for patients who need outpatient or hospital treatment in the COVID 19 pandemic. In studies investigating the presence of mental problems as a result of the decrease in the social support of the patients in this group due to social isolation, the study results indicate that the patients experience negative conditions such as depression, stress, sleep problems, and anxiety (Verma 2020, Alipour et all 2020; Chakeri et all 2020).
Therefore, when quarantined patients are evaluated holistically, there is a need for studies evaluating the effect of telehealth services to increase the quality of life by coping with mental problems such as anxiety and depression. Although there are studies in the related literature showing that telemonitoring can cope with physical problems, improve quality of life, and reduce mental problems such as anxiety and depression, studies showing the effect of telemonitoring given to quarantined patients on anxiety and quality of life are quite limited (Kamei et all 2021; Jahromi et all 2016; Charekei et all 2020; Allipour et all 2020). For this reason, our study was carried out to evaluate the effect of telemonitoring service to be given to patients kept under quarantine during the COVID 19 pandemic on anxiety and quality of life.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tele-monitoring group | Active Comparator | The researchers called the patients in the experimental group on the first day of the quarantine and explained the topics covered in the COVID 19 patient education booklet to the patients. Patient education and follow-up in quarantine took approximately 25-30 minutes for each patient in the experimental group. The patients in quarantine were followed up by the researchers two more times, on the 5th and 9th days of the quarantine. On the 10th and last day of the quarantine, post-test online questionnaires were sent to the patients for the second time, and the data collection phase was ended. |
|
| Plasebo group | No Intervention | The patients in the control group were called by the researchers on the first day of the quarantine and asked to fill in the online pre-test forms. On the 10th day, the last day of the quarantine, the patients were called and the online post-test forms were sent for the second time, and the data were collected. There was no telephone follow up in the control group and the patients received only routine care in the home |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| tele-monitoring | Other | The symptoms of the patients were evaluated by calling the patients on the 1st, 5th, and 9th days of the quarantine by the researchers. |
|
| Measure | Description | Time Frame |
|---|---|---|
| The MOS 36 Item Short Form Health Survey(SF-36) | Scores of SF 36-Quality of Life Scale The scale consists of 8 subscales, including physical function, social function, physical role function, emotional role function, mental health, vitality, pain, and general health, and a total of 36 items. Evaluation in the scale is Likert type except for some items and the last 4 weeks are taken into consideration. Subscales evaluate health between 0-100 and the higher the score, the better the quality of life. | 10 days after |
| Measure | Description | Time Frame |
|---|---|---|
| The Beck Anxiety Scale | The scores of the Beck Anxiety Scale It is a Likert-type assessment tool in which scores ranging from 0 to 3 are given in the 21-item scale. 8-15 points obtained from the scale = Mild anxiety, 16-25 points = Moderate anxiety, 26-63 points = Severe anxiety. While the lowest score that can be taken from the scale is 0, the highest score that can be obtained from the scale is 63. A high total score indicates an increase in anxiety severity |
Not provided
Inclusion Criteria:
- Volunteer patients who were diagnosed with COVID 19, over the age of 18, had no communication problems, were literate, had no diagnosed mental pathology, were able to use smartphones were included in the study
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Arzu Bahar, PhD | Yuksek Ihtisas University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Arzu Bahar | Ankara | Turkey (Türkiye) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D001008 | Anxiety Disorders |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
A Clinical trial with experimental and control groups with
Not provided
Not provided
Not provided
| 10 days after |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D001523 | Mental Disorders |